Exploring molecular mechanism of icaritin against non‑small cell lung cancer EGFR‑TKIs resistance based on network pharmacology and<italic style="font-style: italic"> in vitro </italic>experiments

HAN Yang; SANG Shuliu; ZHOU Hailun; WANG Qin; KANG Xiaohong; GONG Yabin

doi:10.16305/j.1007-1334.2024.24002073

您当前的位置：

首页 >

文章列表页 >

Exploring molecular mechanism of icaritin against non‑small cell lung cancer EGFR‑TKIs resistance based on network pharmacology and in vitro experiments

更新时间：2024-08-31

- Exploring molecular mechanism of icaritin against non‑small cell lung cancer EGFR‑TKIs resistance based on network pharmacology and in vitro experiments
- Shanghai Journal of Traditional Chinese Medicine Vol. 58, Issue 9, Pages: 50-60(2024)
- 作者机构：
  
  1.上海中医药大学附属岳阳中西医结合医院（上海 200437）
  2.新乡医学院第一附属医院（河南新乡 453100）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2024.24002073
  CLC：
- Published：10 September 2024，
  
  Received：28 February 2024，
- 稿件说明：
移动端阅览
韩阳,桑舒柳,周海伦,等.基于网络药理学与体外实验探讨淫羊藿素抗非小细胞肺癌EGFR‑TKIs耐药的分子机制[J].上海中医药杂志,2024,58(9):50-60.

HAN Yang,SANG Shuliu,ZHOU Hailun,et al.Exploring molecular mechanism of icaritin against non‑small cell lung cancer EGFR‑TKIs resistance based on network pharmacology and in vitro experiments[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(9):50-60.
韩阳,桑舒柳,周海伦,等.基于网络药理学与体外实验探讨淫羊藿素抗非小细胞肺癌EGFR‑TKIs耐药的分子机制[J].上海中医药杂志,2024,58(9):50-60. DOI： 10.16305/j.1007-1334.2024.24002073.

HAN Yang,SANG Shuliu,ZHOU Hailun,et al.Exploring molecular mechanism of icaritin against non‑small cell lung cancer EGFR‑TKIs resistance based on network pharmacology and in vitro experiments[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(9):50-60. DOI： 10.16305/j.1007-1334.2024.24002073.

摘要

目的

基于网络药理学与体外实验探讨淫羊藿素抗非小细胞肺癌（NSCLC）表皮生长因子受体-酪氨酸酶抑制剂（EGFR-TKIs）耐药的分子机制。

方法

利用PubChem和化合物靶点预测（Swiss Target Prediction）数据库下载淫羊藿素的简化分子线性输入规范（SMILES）号及作用靶点，通过人类基因（GeneCards）和在线人类孟德尔遗传（OMIM）数据库收集NSCLC耐药疾病靶点，将药物与疾病交集靶点导入STRING数据库分析蛋白质-蛋白质相互作用（PPI）情况，运用Cytoscape 3.9.1软件内置插件计算节点拓扑参数值并筛选核心靶点，采用生物信息学分析平台（DAVID）数据库进行京都基因与基因组百科全书（KEGG）和基因本体（GO）富集分析，构建“淫羊藿素-关键靶点-疾病-通路”图。使用Pymol和Autodock Tools 1.5.7软件进行分子对接。体外实验选用NSCLC耐药株PC9OR研究淫羊藿素对细胞增殖、集落形成、迁移、侵袭和凋亡能力的影响，并对富集得到的核心靶点及关键通路进行验证。

结果

共筛选到淫羊藿素治疗NSCLC耐药的潜在作用靶点1 952个。通过PPI网络节点拓扑参数值筛选得到13个核心靶点，涉及蛋白激酶B（

AKT1

）、雌激素受体α（

ESR1

）、B淋巴细胞瘤2（

BCL2

）、表皮生长因子受体（

EGFR

）等基因。KEGG通路富集分析显示，癌症相关通路、磷脂酰肌醇-3-激酶-蛋白激酶 B（PI3K-AKT）信号通路、EGFR-TKIs耐药通路等可能在淫羊藿素治疗NSCLC EGFR-TKIs耐药的过程中起关键作用。GO富集分析显示，细胞功能涉及信号传导、凋亡过程的负调控、DNA转录的正调控等。分子对接显示淫羊藿素与各核心靶点均具有较强的结合能力。细胞实验表明，淫羊藿素抑制耐药细胞的增殖、集落形成、迁移、侵袭及促进细胞凋亡，并下调

ESR1、AKT1、EGFR

等mRNA表达水平以及PI3K-AKT通路磷酸化磷脂酰肌醇-3-激酶（p-PI3K）、磷酸化蛋白激酶B（p-AKT）的关键蛋白水平。

结论

淫羊藿素可能通过多靶点调控PI3K-AKT通路抑制EGFR-TKIs耐药细胞的增殖、集落形成、迁移、侵袭及促进细胞凋亡，从而发挥抗NSCLC EGFR-TKIs耐药的作用。

Abstract

Objective

To explore the molecular mechanism of icaritin against the resistance to epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKIs） in non-small cell lung cancer （NSCLC） based on network pharmacology and

in vitro

experiments.

Methods

Download the Simplified Molecular Input Line Entry System （SMILES） notation and therapeutic targets of icaritin from PubChem and Swiss Target Prediction databases. Collect NSCLC resistance disease targets using the GeneCards and Online Mendelian Inheritance in Man （OMIM） databases. Import the intersecting targets of the drug and disease into the STRING database to analyze protein-protein interactions （PPI）. Use the Cytoscape 3.9.1 software with built-in plugins to calculate node topological parameters and filter core targets. Perform Kyoto Encyclopedia of Genes and Genomes （KEGG） and Gene Ontology （GO） enrichment analysis using the Database for Annotation， Visualization， and Integrated Discovery （DAVID）， and construct the "icaritin-key target-disease-pathway" map. Conduct molecular docking using Pymol and Autodock Tools 1.5.7 software. In the

in vitro

experiments， NSCLC resistant cell line PC9OR was used to study the effects of icaritin on cell proliferation， colony formation， migration， invasion， and apoptosis， and to verify the core targets and key pathways obtained from the enrichment analysis.

Results

A total of 1 952 p

otential targets for icaritin in treating NSCLC resistance were identified. Through the analysis of topological parameters in the PPI network， 13 core targets were screened， including genes such as protein kinase B （

AKT1

）， estrogen receptor α （

ESR1

）， B-cell lymphoma 2 （

BCL2

）， and epidermal growth factor receptor

（

EGFR

）. KEGG pathway enrichment analysis indicated that cancer-related pathways， the phosphatidylinositol-3-kinase（PI3K）-protein kinose 13（AKT） signaling pathway， and the EGFR-TKIs resistance pathway might play crucial roles in the treatment of NSCLC EGFR-TKIs resistance by icaritin. GO enrichment analysis showed that cellular functions involved signal transduction， negative regulation of apoptosis， and positive regulation of DNA transcription. Molecular docking revealed that icaritin had strong binding affinities with each core target. Cell experiments demonstrated that icaritin inhibited the proliferation， colony formation， migration， invasion of resistant cells， and promoted apoptosis of resistant cells， while downregulating the mRNA expression levels of

ESR1

，

AKT1

， and

EGFR

， as well as the key protein levels of phosphorylated PI3K （p-PI3K） and phosphorylated AKT （p-AKT） in the PI3K-AKT pathway.

Conclusions

Icaritin may exert its anti-NSCLC EGFR-TKIs resistance effect by multi-target regulation of the PI3K-AKT pathway， thereby inhibiting the proliferation， colony formation， migration， invasion of resistant cells， and promoting the apoptosis of EGFR-TKIs resistant cells.

关键词

非小细胞肺癌淫羊藿素表皮生长因子受体-酪氨酸酶抑制剂耐药网络药理学中药研究

Keywords

non-small cell lung cancericaritinepidermal growth factor receptor-tyrosine kinase inhibitorsdrug resistancenetwork pharmacologytraditional Chinese medicine research

references

BRAY F，LAVERSANNE M，SUNG H，et al. Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2024，74（3）：229-263.

LI M，MENG G X，LIU X W，et al. Deep-LC：A novel deep learning method of identifying non-small cell lung cancer-related genes［J］. Front Oncol， 2022， 12： 949546.

李冬梅，张千山，聂冬辉，等. 活血化痰散结方联合安罗替尼治疗老年晚期肺癌疗效及对细胞免疫水平的影响［J］. 中国老年学杂志，2024， 44（10）： 2348-2350.

HENDRIKS L E，KERR K M，MENIS J，et al. Non-oncogene-addicted metastatic non-small-cell lung cancer：ESMO Clinical Practice Guideline for diagnosis，treatment and follow-up［J］. Ann Oncol，2023， 34（4）： 358-376.

MOTTA-GUERRERO R，RECONDO G，CARDONA A，et al. The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer［J］. Crit Rev Oncol Hematol， 2024， 196：104294.

RAMALINGAM S S，VANSTEENKISTE J，PLANCHARD D，et al. Overall survival with Osimertinib in untreated，EGFR-mutated advanced NSCLC［J］. N Engl J Med， 2020， 382（1）： 41-50.

MA Y，ZHAO C，HU H，et al. Liver protecting effects and molecular mechanisms of icariin and its metabolites［J］. Phytochemistry， 2023， 215： 113841.

XIANG L，LI Y，GU X，et al. Nucleolin recognizing silica nanoparticles inhibit cell proliferation by activating the Bax/Bcl-2/caspase-3 signalling pathway to induce apoptosis in liver cancer［J］. Front Pharmacol， 2023， 14： 1117052.

YU Z，GUO J，HU M，et al. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma［J］. ACS Nano， 2020， 14（4）： 4816-4828.

WANG X，ZHENG N，DONG J，et al. Estrogen receptor‑α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells［J］. J Steroid Biochem Mol Biol， 2017， 171： 318-327.

WANG Y，WANG G，LIU Y，et al. Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1［J］. Phytomedicine， 2023， 120： 155062.

LI X，ZHANG W，LIANG L，et al. Natural product-derived icaritin exerts anti-glioblastoma effects by positively modulating estrogen receptor beta［J］. Exp Ther Med， 2020， 19（4）： 2841-2850.

ZHOU C，GU J，ZHANG G，et al. AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity［J］. Oncotarget， 2017， 8（9）： 14736-14747.

SANG S，SUN C，DING R，et al. Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway［J］. Front Pharmacol， 2022， 13： 1019451.

DENNIS Jr G，SHERMAN B T，HOSACK D A，et al. DAVID：database for annotation，visualization，and integrated discovery［J］. Genome Biol， 2003， 4（5）： P3.

ZHANG M，SHUI X，ZHENG X，et al. Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function［J］. Arch Pharm Res， 2023， 46（11-12）： 882-896.

JANACOVA L， STENCKOVA M， LAPCIK P， et al. Catechol-O-methyl transferase suppresses cell invasion and interplays with MET signaling in estrogen dependent breast cancer［J］. Sci Rep，2023，13（1）： 1285.

HUANG X，JIA Z，LI X，et al. Asiaticoside hampers epithelial-mesenchymal transition by promoting PPARG expression and suppressing P2RX7-mediated TGF‑β/Smad signaling in triple-negative breast cancer［J］. Phytother Res， 2023， 37（5）： 1771-1786.

杨宇钦. PPARG/FABP4信号通路介导乳腺癌增殖侵袭能力的体外研究［D］. 广州：南方医科大学，2020.

王永炎. 中医内科学［M］. 上海：上海科学技术出版社，1997： 80-97.

宁伟. 淫羊藿联合放射疗法治疗恶性肿瘤骨转移临床疗效观察［J］. 辽宁中医药大学学报，2021， 23（2）： 33-37.

吴继，刘嘉湘. 刘嘉湘扶正治疗肺癌用药经验［J］. 辽宁中医杂志，2012， 39（4）： 617-619.

吴时礼，徐振晔，邓海滨. 徐振晔运用益气养精抑癌解毒法治疗肺癌经验［J］. 上海中医药杂志，2019， 53（2）： 23-25.

杜林，陈德瑶，顾成娟，等. 仝小林运用淫羊藿、莪术、三七治疗肝癌经验［J］. 吉林中医药，2021， 41（1）： 16-18.

郭敬，陈弘东，周强，等. 仝小林运用淫羊藿经验［J］. 山东中医杂志，2016， 35（4）： 336-338.

ZHENG X，GOU Y，JIANG Z，et al. Icaritin-induced FAM99A affects GLUT1-mediated glycolysis via regulating the JAK2/STAT3 pathway in hepatocellular carcinoma［J］. Front Oncol， 2021， 11： 740557.

李月，李玉瑶，冯海，等. 淫羊藿素通过阻断Notch信号通路抑制肝癌增殖［J］. 中华中医药学刊，2023， 41（11）： 134-137， 285-286.

赵雪强，蒋碧佳，银建华，等. 淫羊藿素对人肺腺癌细胞诱导破骨细胞前体细胞向破骨细胞分化的影响及机制［J］. 山东医药，2021， 61（4）： 5-9.

LU X，XUE B，ZHANG T，et al. Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway［J］. Gen Physiol Biophys，2019，38（6）：525-533.

SOFI S，MEHRAJ U，JAN N，et al. Clinicopathological significance and expression pattern of Bcl2 in breast cancer：A comprehensive in silico and in vitro study［J］. Saudi J Biol Sci， 2024， 31（2）： 103916.

ZHANG L，YAN T，WANG W，et al. AKT1 is positively regulated by G-quadruplexes in its promoter and 3'-UTR［J］. Biochem Biophys Res Commun， 2021， 561： 93-100.

ZHU K，YANG X，TAI H，et al. HER2-targeted therapies in cancer：a systematic review［J］. Biomark Res， 2024， 12（1）： 16.

TSAI H P，LIN C J，LIEU A S，et al. Galectin-3 mediates tumor progression in astrocytoma by regulating glycogen synthase kinase-3β activity［J］. Curr Issues Mol Biol， 2023， 45（4）： 3591-3602.

NEUPANE N，BAWEK S，GURUSINGHE S，et al. Oral SERD，a novel endocrine therapy for estrogen receptor-positive breast cancer［J］. Cancers （Basel）， 2024， 16（3）： 619.

LEDINEK Z，SOBOCAN M，KNEZ J. The role of CTNNB1 in endometrial cancer［J］. Dis Markers， 2022， 2022： 1442441.

WANG Y，JIANG S. The role of ADRB2 gene polymorphisms in malignancies［J］. Mol Biol Rep， 2021， 48（3）： 2741-2749.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Paning Ⅰ Formula on oxidative stress‑mediated ferroptosis pathway in dopaminergic neurons of PD mice

Network pharmacology， in vivo and in vitro research on indirubin inhibiting Lewis lung carcinoma by down‑regulating Cyclin A2 and arresting cell cycle

Transcriptome characteristics of hypothalamus and pituitary in rats with bilateral ovariectomy and regulatory effect of Erxian Decoction

Study on effects of oridonin on glutathione metabolism network in esophageal squamous cell carcinoma cells

Network pharmacology and experimental study‑based research on effects of baicalin on apoptosis in Hepa1‑6 hepatocellular carcinoma cells

Related Author

WAN Yuling

CHEN Yanjun

CHEN Jingwen

XIN Feng

ZENG Jie

WANG Ruizhen

ZHOU Shengqiang

LIU Fang

Related Institution

Graduate School， Hunan University of Traditional Chinese Medicine

Studio of National Chinese Medicine Master LIU ZUYI at Hunan Integrated Traditional Chinese and Western Medicine Hospital

School of Traditional Chinese Medicine， Shanghai University of Traditional Chinese Medicine

Shanghai Key Laboratory of Health Assessment and Identification， Shanghai University of Traditional Chinese Medicine

Department of Medical Cosmetic Center， Shanghai Skin Disease Hospital

⁰

Exploring molecular mechanism of icaritin against non‑small cell lung cancer EGFR‑TKIs resistance based on network pharmacology and in vitro experiments

DOI：10.16305/j.1007-1334.2024.24002073

摘要

Abstract

关键词

Keywords

references